Chief Executive Officer

Mark Levick

Mark Levick leads Alvotech with over 30 years of experience in the healthcare and pharmaceutical industries, blending a clinical background with deep business expertise. Most recently, he oversaw the successful approval in major markets of five of the earliest biosimilars medicines as Global Head of Biopharmaceutical Development for Sandoz, a division of Novartis. After seeing the life-changing impact that biosimilars could have, he became a passionate advocate for broader access to biologic medicines and he brings that passion to Alvotech.

Previously Mark also held roles of increasing responsibility at Novartis in the USA and Switzerland, including SVP of Respiratory Development, VP of Clinical Development for Immunology, Transplantation and Dermatology, and Head of the Infectious Disease Clinical Science and Biologics Units, all roles in which he played a pivotal role in the approval of multiple innovative biologic medicines. He rounds out his experience with leadership positions in clinical pharmacology and translational medicine with GlaxoSmithKline in both the UK and USA.  

Prior to entering the pharmaceutical industry, Mark served as a medical reviewer at the UK’s Medicines and Healthcare Products Regulatory Agency and the European Medicines Agency, following more than 10 years practicing as a specialist physician in teaching hospitals in the UK and Australia. Mark has a medical degree from the University of Newcastle, Australia, and is board certified in both infection medicine and general medicine. He studied at the University of Cambridge in the UK as a Commonwealth scholar and holds a PhD in vaccine development from Cambridge University.